Stocks of Ginkgo Bioworks Holdings Inc (NYSE:DNA) traded higher last session on Wall Street, up 15.08% to $0.99.
DNA stock price is now -12.98% away from the 50-day moving average and -35.65% away from the 200-day moving average. The market capitalization of the company currently stands at $2.01B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $3.50 to $2.50, Raymond James Downgraded its rating from Outperform to Mkt Perform for Ginkgo Bioworks Holdings Inc (NYSE: DNA). , while ‘Goldman’ rates the stock as ‘Sell’
In other news, Dmytruk Mark E., insider sold 51,169 shares of the company’s stock on Apr 02 ’24. The stock was sold for $53,727 at an average price of $1.05. Upon completion of the transaction, the insider now directly owns 865,079 shares in the company, valued at $0.86 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 04 ’24, Dmytruk Mark E. sold 38,826 shares of the business’s stock. A total of $48,765 was realized by selling the stock at an average price of $1.26. This leaves the insider owning 808,125 shares of the company worth $0.8 million. A total of 33.65% of the company’s stock is owned by insiders.
During the past 12 months, Ginkgo Bioworks Holdings Inc has had a low of $0.74 and a high of $2.55. As of last week, the company has a debt-to-equity ratio of 0.22, a current ratio of 6.11, and a quick ratio of 6.11.
According to the Biotechnology Company, earnings per share came in at -0.11, missing analysts’ expectations of -0.09 by -0.02. This compares to -$0.06 EPS in the same period last year. The net profit margin was -355.08% and return on equity was -63.02% for DNA. The company reported revenue of $34.76 million for the quarter, compared to $98.28 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -64.64 percent. For the current quarter, analysts expect DNA to generate $46.04M in revenue.
